Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100

BACKGROUND: Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No reliable markers are available for predicting bevacizumab-induced hypertension. METHODS: A genome-wide association study (GWAS) was performed in the phase III bevacizumab-based adjuvant breast cancer tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, B P, Li, L, Shen, F, Miller, K D, Radovich, M, O'Neill, A, Gray, R J, Lane, D, Flockhart, D A, Jiang, G, Wang, Z, Lai, D, Koller, D, Pratt, J H, Dang, C T, Northfelt, D, Perez, E A, Shenkier, T, Cobleigh, M, Smith, M L, Railey, E, Partridge, A, Gralow, J, Sparano, J, Davidson, N E, Foroud, T, Sledge, G W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Genetics and Genomics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453857/
https://www.ncbi.nlm.nih.gov/pubmed/25117820
http://dx.doi.org/10.1038/bjc.2014.430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453857/
https://www.ncbi.nlm.nih.gov/pubmed/25117820
http://dx.doi.org/10.1038/bjc.2014.430

Ejemplares similares